Congress raises vaccine prices to fund injury claims—but keeps manufacturers immune

What it does

This bill modernizes the federal Vaccine Injury Compensation Program by increasing compensation awards for vaccine-related deaths and injuries (from unspecified baseline to $600,000 each), expanding the program to cover COVID-19 vaccines, adding new vaccines to the injury compensation table, and raising the federal excise tax on vaccines from an unspecified rate to $2.20 per dose. It also requires more special masters to hear claims faster and expands the statute of limitations for filing injury claims to 5 years.

Why we flagged it

The bill's core function is to modernize and expand the National Vaccine Injury Compensation Program with higher awards and faster processing, while simultaneously imposing a new/increased excise tax on vaccine sales. The tax mechanism appears designed to fund the expanded compensation program, but creates a policy tension between incentivizing vaccination and raising its cost.

What the text implies

• The $2.20 excise tax increase may be passed to consumers, raising vaccine prices and potentially reducing vaccination rates—especially among uninsured and low-income populations—which could undermine public health goals even as the bill expands injury compensation.
• COVID-19 vaccines are explicitly added to the compensation program and injury table, opening a new claims pathway for individuals who previously had limited recourse under the Countermeasures Injury Compensation Program (CICP), which had stricter liability protections for manufacturers.

The full analysis lists 5 implications of this text.

Who stands to gain

vaccine manufacturers (PFE, JNJ, BMY, GH, DVA) via excise tax revenue funding compensation program,; injured vaccine recipients via higher compensation awards and faster claim processing; special masters and administrative staff via expanded program staffing